U of Washington, Pharmigene Resolve IP Dispute, Reach Licensing Deal | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The University of Washington and Pharmigene today announce the resolution of a patent dispute and the subsequent licensing of technology to Pharmigene for determining proper dosing for the anti-coagulant drug warfarin.

The agreement settles a patent interference "concerning previously competing applications that describe methods to determine proper dosing of … warfarin," the two firms said in a joint statement. No additional details were provided.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.